Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Trial details
- Registry ID
- NCT01995058
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as XL184
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058 | Exelixis | Phase 2 | Terminated | 2014-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |